Roche Nimblegen and High Throughput Genomics (HTG), provider of the quantitative Nuclease Protection Assay (qNPA), have entered into a supply agreement.
Under the agreement, Roche NimbleGen will provide HTG with high-density, multiplex DNA microarray slides for advanced gene-expression analysis.
HTG will apply the company's quantitative nuclease-protection assay (qNPA) process to the microarrays to enable researchers to quickly and efficiently measure the gene-expression levels in a variety of sample types.
The agreement enhances HTG's existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays.
Sample preparation using qNPA technology allows for a simpler, more cost-effective workflow versus traditional labelling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high-density microarray, providing in-depth gene expression information.
